Intracoronary recombinant human pro-urokinase and nicorandil during primary PCI in patients with acute ST-elevation myocardial infarction:a randomized trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015932

Enrollment

Unknown

Registered

2018-04-29

Start date

2018-05-01

Completion date

Unknown

Last updated

2018-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ST-elevation myocardial infarction

Interventions

rh-proUK group:rh-proUK (10mg, 10ml)

nicorandil group:nicorandil (2mg, 10ml)

rh-proUK+nicorandil group:rh-proUK (10mg, 10ml)+nicorandil (2mg, 10ml)

Control group:NS 10ml

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 18 to 75 years old, male or female; 2) Symptoms are less than 12 hours, Patients with ST elevation myocardial infarction, indications for thrombolysis, and exclusion of thrombolytic contraindications; 3) Sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients who have undergone intravenous thrombolytic; 2) History of intracranial hemorrhage; 3) Ischemic stroke within 3 months; 4) Suspicious aortic dissection; 5) Active bleeding or bleeding (including menstruation); 6) Severe head and face injuries within 3 months; 7) Severe or uncontrolled hypertension (SBP>180 mmHg or DBP>110 mmHg); 8) Severe trauma or major surgery or invasive blood vessel bleeding within 3 weeks; 9) Patients with malignant tumors; 10) Severe liver and kidney dysfunction; 11) Pregnant, breast-feeding women or women who may be pregnant; 12) Allergic to or have contraindications to research drugs or contrast agents; 13) Patients after coronary artery bypass surgery; 14) Coronary arteriography shows that the guilty culprit has TIMI grade 3 and no significant thrombotic signs; 15) Clinical study in which the patient participated at the same time; 16) Patients with cardiogenic shock; 17) Medications with phosphodiesterase 5 blocking (sildenafil, etc.); 18) The surgeon thinks it is not suitable to include the patient.

Design outcomes

Primary

Measure	Time frame
TIMI frame count;corrected TIMI frame count;MBG;TMPG;No reflow/slow reflow incidence;infarct size;major adverse cardiac events (30 days);Detection of inflammatory and oxidative stress factor expression;	—

Countries

China

Contacts

Public ContactHong Lang

Jiangxi Provincial People's Hospital

honglang1330@126.com+86 13803501330

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026